Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Fig. 1

Representative cases of HPD (defined as a fourfold of TGR or TGKR) in patients with advanced HCC treated Atez/Bev. A and B Changes in CT scans and target lesions tumor diameter in the liver of the case who received Atez/Bev as the first-line treatment. C and D Changes in CT scans and target lesion tumor diameter in the liver of the case who received Atez/Bev as the second-line treatment. HPD indicates hyperprogressive disease

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us